Skip to nav Skip to content

Doctor reviewing chart

The multiple myeloma specialists at Moffitt Cancer Center are exclusively focused on the treatment of this unique malignancy, providing comprehensive and highly targeted therapies based on each patient’s specific needs. We take a unique, team-based approach to multiple myeloma treatment; every patient’s treatment plan is assembled, administered and routinely reviewed by a group of specially trained doctors. We believe that several expert opinions are better than one – that’s why we make it possible for our patients to consult with numerous world-class medical professionals in a single location.

The multiple myeloma specialists in our Malignant Hematology Program include:

  • Chemotherapy specialists (medical oncologists)
  • Medical professionals who create and refine radiation therapy plans (radiation oncologists)
  • Medical professionals who administer radiation therapy (radiation therapists)
  • Lab specialists who review blood tests and tissue samples (pathologists)
  • Nurses who have specific experience caring for cancer patients (oncology nurses)

We also have a team of invaluable supportive care providers who are focused solely on helping our patients obtain the highest possible quality of life throughout treatment and recovery. This team offers pain and symptom management services along with emotional and social support, furthering Moffitt’s goal of providing total-patient care for each individual.

Our multiple myeloma specialists excel not only in their clinical efforts, but also in their research endeavors. Our malignant hematology doctors are continually furthering developments in their wide-ranging areas of interest, such as therapies for recurrent myeloma and bone marrow treatment options. The progress we make each day in the lab is continually bringing us closer and closer to an eventual cure.

Call 1-888-663-3488 or submit a new patient registration form online to request an appointment with our multiple myeloma specialists. No referral is required to make an appointment.

  • Malignant Hematology Leadership
    Jeffrey  Lancet, MD
    Department Chair, Malignant Hematology
    Program Lead, Malignant Hematology

    Program

    Malignant Hematology

    Title

    Chair, Department of Malignant Hematology

    Specialty

    Hematology

    5 (133)
    Rami  Komrokji, MD

    Program

    Malignant Hematology

    Title

    Vice Chair, Department of Malignant Hematology

    Specialty

    Hematology/Oncology

    4.9 (226)
  • Multiple Myeloma BMT and Cellular Immunotherapy Specialists

    Meet the BMT and cellular immunotherapy specialists who treat multiple myeloma.

    Melissa  Alsina, MD

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Blood and Marrow Transplant and Cellular Immunotherapy

    4.9 (206)
    Claudio  Anasetti, MD

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Blood and Marrow Transplant and Cellular Immunotherapy

    Doris  Hansen, MD

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Blood and Marrow Transplant and Cellular Immunotherapy

    5 (18)
    Frederick  Locke, MD
    Department Chair, Blood and Marrow Transplant and Cellular Immunotherapy
    Program Lead, Blood and Marrow Transplant and Cellular Immunotherapy

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Title

    Program Co-Leader, Immuno-Oncology; Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Blood and Marrow Transplant and Cellular Immunotherapy

    Taiga  Nishihori, MD

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Blood and Marrow Transplant and Cellular Immunotherapy

    4.9 (40)
    Jose  Ochoa-Bayona, MD

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Blood and Marrow Transplant and Cellular Immunotherapy

    4.9 (33)
    Leo  Malpica

    Specialty

    Blood and Marrow Transplant and Cellular Immunotherapy